Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-09-12
2006-09-12
Wang, Andrew (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100
Reexamination Certificate
active
07105657
ABSTRACT:
Methods are provided for the inhibition of metastasis of cancer cells expressing MUC4, metastatic pancreatic cancer cells.
REFERENCES:
patent: 5530114 (1996-06-01), Bennett et al.
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 5981279 (1999-11-01), Weiss
patent: 6001651 (1999-12-01), Bennett et al.
patent: 6716627 (2004-04-01), Dobie
patent: 2003/0077568 (2003-04-01), Gish et al.
Moniaux et al. (1999) Biochem. J. 338:325-333.
Andrianifahanana, M., et al., “Mucin (Muc) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: A potential role of MUC4 as a tumor marker of diagnostic significance”; Clin. Cancer. Res., 7:4033-4040 (2001).
Balague, C., et al., “Altered Expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell lines”; Gastroenterology 106:1054-1061 (1994).
Caldas, C., et al., “Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia” Cancer Res.; 54: 3568-3573 (1994).
Choudhury, A., et al., “MUC4 Mucin Expression in Human Pancreatic Tumors is Affected by Organ Environment: Possible Role of TGFbeta2”; Abstract, Br. J. Cancer, 90(3): 657-64 (2004).
Day, J.D., et. al., “Immunohistochemical evaluation of HER-2
eu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms”; Hum. Pathol. 27: 119-124 (1996).
Dimagno, E.P., et. al., “AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma”; American Gastroenterological Association, Gastroenterology 117: 1464-1484 (1999).
Hameed, M., et. al., “Expression of p53 nucleophosphoprotein in in situ pancreatic ductal adenocarcinoma: an immunohistochemical analysis of 100 cases”; Lab. Invest. 70: 132A (1994).
Hollingsworth, M.A., et. al., “Expression of MUC1, MUC2, MUC3, and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines”; Int. J. Cancer 57: 198-203 (1994).
Khorrami, A.M., “Purification and characterization of a human pancreatic adenocarcinoma mucin”; J. Biochem. Jan; 131(1):21-9 (2002).
Komatsu, M., et al., “Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor”; Oncogene 20(4): 461-470 (2001).
Komatsu, M., et al., “Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein”; Int. J. Cancer, 87:480-486 (2000).
Komatsu, M., et al., “Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells”; Cancer Research, 59: 2229-2236 (1999).
Luttges, J., et. al., “The K-ras mutation pattern in pancreatic ductal adenocarcinoma usially is identical to that in associated normal hyperplastic, metaplastic ductal epithelium”; Cancer 85: 1703-1710 (1999).
Nollet, S., et. al., “Human mucin gene MUC4: Organization of its 5′-region and polymorphism of its central tandem repeat array”; Biochem. J. 15: 739-748 (1998).
Parker, S.L., et. al., “Cancer statistics, 1996”; Cancer J. Clin. 46:5-27 (1996).
Schwartz, M.J., et al., “MUC4 expression increases progressively in pancreatic intraepithelial neoplasia”; Am. J. Clin. Pathol., 117:791-796 (2002).
Tada, M., et. al., “Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease”; Gastroenterology 110: 227-231 (1996).
Walsh, M.D., et. al., “Expression of MUC2 epithelial mucin in breast carcinoma”; J. Clin. Pathol. 46: 922-925 (1993).
Warshaw, A.L., et. al., “Pancreatic carcinoma”; N. Engl. J. Med. 326: 455-465 (1992).
Wilentz, R.E., et. al., “Immunohistochemistry labeling for Dpc4 mirrors genetic status in pancreatic and peripancreatic adenocarcinomas: a new marker of DPC4 inactivation”; Am. J. Pathol. 156: 37-43 (2000).
Terris, B., et al., “Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions”; J. Pathol. 197(5): 632-637 (2002).
Batra Surinder K.
Moniaux Nicolas
Singh Ajay P.
Board of Regents of the University of Nebraska
Dann Dorfman Herrell and Skillman
Rigaut Kathleen D.
Wang Andrew
Wollenberger Louis V.
LandOfFree
Compositions and methods for inhibiting pancreatic cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting pancreatic cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting pancreatic cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3556538